(Q44332318)

2 December 2017

title

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up (English)

1 reference

2 December 2017

1 reference

4

Stein Kaasa

1 reference

2 December 2017

Roy M Bremnes

1

1 reference

2 December 2017

Stein Sundstrom

2

1 reference

2 December 2017

Ulf Aasebø

3

1 reference

2 December 2017

Reidulv Hatlevoll

5

1 reference

2 December 2017

Steinar Aamdal

6

1 reference

2 December 2017

Norweigian Lung Cancer Study Group

7

1 reference

2 December 2017

publication date

1 March 2003

1 reference

2 December 2017

1 reference

2 December 2017

volume

39

1 reference

2 December 2017

issue

3

1 reference

2 December 2017

page(s)

303-313

1 reference

2 December 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Management of small cell lung cancer: current state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

New chemotherapy agents for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

LDH or NSE or LDH and NSE as pretreatment prognostic factors in small cell lung cancer? A commentary

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Prognostic factors and prognostic staging system for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Predictive and prognostic factors in small cell lung cancer: current status.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): The role of sex as a predictor for survival

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Small-cell carcinoma of the lung: derivation of a prognostic staging system.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Prognosis at presentation of small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

The relative value of conventional staging procedures for developing prognostic models in extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2802%2900508-1

7 January 2021

10.1016/S0169-5002(02)00508-1

Identifiers

DOI

1 reference

2 December 2017

1 reference